Home Finance Neurovascular Company Perfuze Raises €22.5m ($25m) Series A for New Stroke Treatment – Yahoo Finance

Neurovascular Company Perfuze Raises €22.5m ($25m) Series A for New Stroke Treatment – Yahoo Finance

0
Neurovascular Company Perfuze Raises €22.5m ($25m) Series A for New Stroke Treatment – Yahoo Finance

Perfuze develops catheter-based technology for treating acute ischemic stroke
Financing was led by new investors LSP and Seroba Life Sciences and joined by new investor SV Health Investors and existing investors
GALWAY, Ireland, February 09, 2022–(BUSINESS WIRE)–Perfuze, a medical device company developing next-generation catheter-based aspiration technology to treat large vessel occlusion acute ischemic stroke, has closed a €22.5 million Series A investment round. Proceeds from the financing will be used to drive the next stage of US clinical study and regulatory clearance of its Millipede System. The funds will also be used to support ongoing development of new products and to initiate commercialization of its technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220208005643/en/
https://www.perfuze.com/our-solution
The Series A funding was led by new investors LSP, investing from its LSP Health Economics Fund 2, and Seroba Life Sciences. The round was also supported by new investor SV Health Investors, investing from its Medtech Convergence Fund and existing investors Earlybird, the HBM-MedFocus Fund, Enterprise Ireland and a syndicate of Irish business veterans and stroke physicians.
With the closing of the Series A financing round, Anne Portwich, Partner at LSP, and Daniel O’Mahony, Partner at Seroba Life Sciences, will join the Perfuze board of directors and Megan MacDonagh, Senior Associate at SV Health investors will join as a Board Observer.
"Perfuze has a technology with the potential to significantly improve outcomes for stroke patients," says Anne Portwich, Partner at LSP. "We are delighted to support the company and its management team to expand as it pushes towards getting its life-saving technology to market."
Speaking on why Seroba decided to invest in Perfuze, Daniel O’Mahony said "Seroba recognizes that for patients who have suffered a stroke event, time is brain. Perfuze’s Millipede technology will allow for rapid and successful blood vessel recanalization which is vital to improve the patient’s functional status and reduce mortality following a stroke event."
Wayne Allen, CEO of Perfuze, says: "We are delighted to have completed our Series A financing with such experienced investors and this capital facilitates our continued growth and development. We believe that the Perfuze Millipede System is the next wave of thrombectomy technology in the rapidly growing stroke market and has the potential to positively impact the lives of thousands of stroke patients."
According to the WHO, stroke is the second leading global cause of death and a leading cause of disability. An ischemic stroke occurs when a blood vessel in the brain is blocked by a clot, preventing blood flow. Perfuze’s technology aims to provide superior clinical outcomes in shorter procedural times, resulting in safe cost-effective therapy.
About Perfuze
Based in Galway, Ireland, Perfuze has developed super-bore diameter aspiration technology that has the capability to navigate the complex neurovascular anatomy. Perfuze’ pipeline of products are designed to facilitate fast, complete clot removal during acute ischemic stroke. Perfuze has CE Mark approval for its first device, Millipede 088 and has successfully treated its first cohort of patients. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins, who have over 35 years combined medtech experience. This is the second medtech company they have co-founded; the previous company, Embo Medical, was acquired by CR Bard in 2016. For more information, please visit www.perfuze.com
About LSP
LSP is a European investment firm providing financing for life sciences and health care companies. LSP’s management has raised over $3.5 billion (€3 billion) and supported the growth of 150 companies since it started to invest in 1988, including signature deals such as Argenx, Crucell and Neuravi. With offices in Amsterdam, Munich and Boston, LSP currently has the possibility to invest through five strategies, each having a distinctive investment scope and a dedicated team: LSP 7 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; LSP Public targets public healthcare companies; and EBAC is LSP’s SPAC exclusively focusing on European biotech. LSP is an active contributor to the global life sciences industry and the European life science eco-system by assuming roles as initiators, founders and board members in various private and public bodies and organizations, for example being founder and board member of the Oncode Institute. For more information: lspvc.com.
About Seroba Life Sciences
Seroba is a European life sciences venture capital firm focused on investing in winning innovations in biotech and medtech. The team has deep investment and industry experience enabling Seroba to help entrepreneurs realise their ambitions whilst creating value for investors. The firm has a number of funds under management and has built a portfolio of investee companies across multiple indications. Seroba partners with entrepreneurs to create and build businesses around extraordinary science.
Follow our story at www.seroba-lifesciences.com
About SV Health Investors
SV Health Investors is a leading healthcare fund manager investing in tomorrow’s healthcare breakthroughs. The SV family of funds invests across stages, geographic regions and sectors, with expertise spanning healthcare services / technology, medical products, biotechnology, dementia and public equities. With approximately $2.7B in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 200 companies with more than 90 of these having achieved successful acquisitions or IPOs. The Medtech Convergence Fund (MCF) is a seed and early-stage venture capital fund focused on the increasing convergence of medical technology with software, telecommunications, and new service models to create solutions to some of the most significant health challenges. For more information: svhealthinvestors.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005643/en/
Contacts
Wayne Allen, CEO
Perfuze
Email: wayne@perfuze.com
Shares of Chinese electric vehicle (EV) maker Nio (NYSE: NIO) were trading higher on Tuesday morning, after a Wall Street analyst initiated coverage of the company with a strongly bullish note. As of 11:30 a.m. ET, Nio's American depositary shares were up about 2.3% from Monday's closing price. In a new note on Tuesday, Barclays analyst Jiong Shao initiated coverage of Nio with an overweight rating and a price target of $34.
Shares of Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) surged close to new highs following a period of strong revenue growth in the fourth quarter of 2021, ended Dec. 31, 2021. Not only did Alphabet deliver impressive revenue growth of 32%, but it also announced a 20-for-1 stock split. If approved by shareholders, Alphabet will issue 19 additional shares for every share owned on the record date of July 1, 2022.
Stock of Facebook parent Meta Platforms may finally be bouncing off rock bottom following a historic collapse in value. But there's a debate to be had about dip-buying.
Stock splits usually work, and the 20-for-1 split by Google's parent company Alphabet may spark a wave.
Every investor in Gevo, Inc. ( NASDAQ:GEVO ) should be aware of the most powerful shareholder groups. Large companies…
Based on a wide gamut of Wall Street price targets, select analysts and investment banks foresee the possibility of these ultra-popular stocks crashing in 2022. There might not be a more popular stock with a wider range of expected outcomes from Wall Street than electric vehicle (EV) manufacturer Tesla Motors (NASDAQ: TSLA). In the other column is JPMorgan analyst Ryan Brinkman, who, even after recently upping his firms' price target on Tesla, expects shares to plummet 65% to $325.
Shares of Teva Pharmaceutical Industries Ltd. shed 1.2% in premarket trading Wednesday, after the Israel-based generic drug maker reported fourth-quarter profit that topped expectations but revenue that missed, as COVID-19 continued to impact patient behavior and prescribing patterns. Teva swung to a net loss of $159 million, or 14 cents a share, from net income of $150 million, or 14 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of 77 cents top
On Friday, Clorox's (NYSE: CLX) share prices plummeted 14.5% after the company reported worse-than-expected fiscal year 2022 (FY22) second-quarter results. Here's what separates P&G from Clorox and a look at how to approach investing in each stock now. Clorox management said it expects FY22 organic sales to decline by 1% to 4% year over year, its diluted earnings per share (EPS) to decline by 27% to 32%, and its gross margin to be just 36.1% for the coming year, compared to 45%-plus gross margins in FY20 and 43%-plus margins in FY21.
Stock futures opened higher Tuesday evening as investors considered another batch of solid quarterly corporate earnings results and looked ahead to more reports.
Not surprisingly, online retail spending is expected to grow at nearly 11% per year through 2025, reaching $7.4 trillion, according to eMarketer. Not surprisingly, Shopify has consistently posted stellar financial results. Over the past year, revenue soared 71% to $4.2 billion, gross margin expanded 150 basis points to 54.5%, and free cash flow rocketed 150% higher to $458.2 million.
CVS Health stock was falling after reporting better-than-expected earnings Wednesday but confirming full-year guidance that appeared to disappoint. The company reported revenue of $76.6 billion for the fourth-quarter ending in December, up 10.1% compared with the prior year, beating the FactSet consensus of $75.6 billion. Adjusted earnings per share were $1.98, which topped the FactSet consensus of $1.83.
The results will be a chance for the company to deliver on the upbeat thesis shared by many boosters for the stock.
It isn't an easy environment for a growth fund. Sometimes it's best to just avoid the worst performers.
Investors didn't understand how perfect this deal was until Activision released its fourth-quarter financial results.
Last week, the U.S. stock market made history in two starkly contrasting ways. On Thursday, Meta Platforms stock fell 26% — wiping out $232 billion of its market cap — the largest ever market cap loss by any U.S. company in a single day. On Friday, Amazon (NASDAQ: AMZN) stock surged 13.5%, adding $190 billion in market cap — the largest ever gain by a single U.S company in a day.
Shares of vaccine makers rebound Wednesday after Pfizer's 2022 sales guidance fell short of Wall Street's bullish expectations.
Heather Morgan and Ilya Lichtenstein were arrested for laundering Bitcoin stolen from Bitfinex in 2016
CVS earnings topped estimates, though guidance implies an EPS dip in 2022. CVS stock slipped early Wednesday.
In this article, we will discuss the 10 best dividend stocks to buy according to Sculptor Capital. You can skip our detailed analysis of the hedge fund and its developments, and go directly to read 5 Best Dividend Stocks to Buy According to Sculptor Capital. Sculptor Capital, formerly known as OZ Capital Management, is a […]
The stock markets have started off 2022 with increased volatility, and that’s opened up opportunities for investors – especially for investors willing to shoulder some additional risk. The sharp decline in January lowered prices, while the rapid swings we’ve seen in recent trading sessions makes it possible to take advantage of the lowered entry point. A market situation like this should naturally bring investors’ attention to the penny stocks. These low-cost equities, typically priced below $5

source

LEAVE A REPLY

Please enter your comment!
Please enter your name here